Figure 6 Effect of β‐glucosylceramide on CD4 and CD8 lymphocyte distribution: the beneficial effects of β‐glucosylceramide in the two models were associated with opposite effects on intrahepatic and peripheral lymphocyte distribution. In the experimental colitis model, β‐glucosylceramide‐mediated alleviation of colitis was associated with an increased splenic‐to‐intrahepatic CD4:CD8 ratio (groups A and B), suggesting an increased intrahepatic CD8 lymphocyte trapping. By contrast, the anti‐tumour effect of β‐glucosylceramide in the HCC model was associated with a decreased ratio (groups E and F), suggesting a decreased intrahepatic CD8 lymphocyte trapping. In naive animals (groups C and G), administration of β‐glucosylceramide led to an increase in the ratio (groups C v D, and G v H).